You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 18, 2024

~ Buy the INVOKAMET (canagliflozin; metformin hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

INVOKAMET Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Invokamet, and when can generic versions of Invokamet launch?

Invokamet is a drug marketed by Janssen Pharms and is included in two NDAs. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty-nine patent family members in forty-seven countries.

The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Invokamet

Invokamet was eligible for patent challenges on March 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 26, 2029. This may change due to patent challenges or generic licensing.

There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for INVOKAMET
Drug Prices for INVOKAMET

See drug prices for INVOKAMET

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for INVOKAMET
Generic Entry Date for INVOKAMET*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for INVOKAMET
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
INVOKAMET Tablets canagliflozin; metformin hydrochloride 50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg 204353 6 2017-03-29

US Patents and Regulatory Information for INVOKAMET

INVOKAMET is protected by twelve US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of INVOKAMET is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting INVOKAMET


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline form of 1-(.beta.-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS

Crystalline form of 1-(.beta.-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS

Crystalline form of 1-(.beta.-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS

Glucopyranoside compound
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Glucopyranoside compound
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS

Glucopyranoside compound
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS

Glucopyranoside compound
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS

Crystalline form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS

Crystalline form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS

Crystalline form of 1-(.beta.-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethy- l]benzene hemihydrate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF TYPE 2 DIABETES MELLITUS

Glucopyranoside compound
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-004 Sep 20, 2016 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-002 Sep 20, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-001 Sep 20, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-002 Sep 20, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-003 Aug 8, 2014 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Janssen Pharms INVOKAMET canagliflozin; metformin hydrochloride TABLET;ORAL 204353-001 Aug 8, 2014 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Janssen Pharms INVOKAMET XR canagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 205879-002 Sep 20, 2016 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for INVOKAMET

When does loss-of-exclusivity occur for INVOKAMET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 4099
Estimated Expiration: ⤷  Try a Trial

Patent: 7510
Estimated Expiration: ⤷  Try a Trial

Patent: 8450
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 07329895
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 0718882
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 71357
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 07003487
Estimated Expiration: ⤷  Try a Trial

China

Patent: 1573368
Estimated Expiration: ⤷  Try a Trial

Patent: 2675299
Estimated Expiration: ⤷  Try a Trial

Patent: 2675380
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 10719
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 861
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0140254
Estimated Expiration: ⤷  Try a Trial

Cyprus

Patent: 14969
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 02224
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 099489
Estimated Expiration: ⤷  Try a Trial

El Salvador

Patent: 09003285
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 7103
Estimated Expiration: ⤷  Try a Trial

Patent: 0970540
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 02224
Estimated Expiration: ⤷  Try a Trial

Guatemala

Patent: 0900151
Estimated Expiration: ⤷  Try a Trial

Honduras

Patent: 09001135
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 9032
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 59788
Estimated Expiration: ⤷  Try a Trial

Patent: 10511602
Estimated Expiration: ⤷  Try a Trial

Malaysia

Patent: 3702
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 09005857
Estimated Expiration: ⤷  Try a Trial

Montenegro

Patent: 829
Estimated Expiration: ⤷  Try a Trial

New Zealand

Patent: 7545
Estimated Expiration: ⤷  Try a Trial

Nicaragua

Patent: 0900113
Estimated Expiration: ⤷  Try a Trial

Norway

Patent: 4354
Estimated Expiration: ⤷  Try a Trial

Patent: 091778
Estimated Expiration: ⤷  Try a Trial

Panama

Patent: 59401
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 081201
Estimated Expiration: ⤷  Try a Trial

Patent: 110841
Estimated Expiration: ⤷  Try a Trial

Patent: 130591
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 02224
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 02224
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 274
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 02224
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 0903941
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 1146095
Estimated Expiration: ⤷  Try a Trial

Patent: 090086282
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 56640
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 03325
Estimated Expiration: ⤷  Try a Trial

Patent: 0829259
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 135
Estimated Expiration: ⤷  Try a Trial

Uruguay

Patent: 730
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVOKAMET around the world.

Country Patent Number Title Estimated Expiration
Uruguay 32778 TERAPIA DE COMBINACIÓN PARA EL TRATAMIENTO DE LA DIABETES ⤷  Try a Trial
Iceland 8444 Staðgengin indól-o-glúkósíð ⤷  Try a Trial
Nicaragua 200900113 FORMA CRISTALINA DEL HEMIHIDRATO DE 1-(Beta-D-GLUCOPIRANOSIL)-4-METIL-3-[5-(4-FLUOROFENIL)-2-TIENILMETIL] BENCENO. ⤷  Try a Trial
Iceland 8446 Staðgengin bensimidasól-, benstríasól- og bensimidasólon-o-glúkósíð ⤷  Try a Trial
Denmark 2451482 ⤷  Try a Trial
Norway 333933 ⤷  Try a Trial
South Korea 20070065454 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDENT TRANSPORTER ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for INVOKAMET

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1651658 CR 2014 00024 Denmark ⤷  Try a Trial PRODUCT NAME: CANAGLIFLOZIN; REG. NO/DATE: EU/1/13/884/001-008 20131119
1651658 2014C/027 Belgium ⤷  Try a Trial PRODUCT NAME: CANAGLIFLOZINE; AUTHORISATION NUMBER AND DATE: EU/1/13/884 20131119
1651658 CA 2014 00024 Denmark ⤷  Try a Trial PRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115
1651658 92426 Luxembourg ⤷  Try a Trial PRODUCT NAME: CANAGLIFLOZINE
1651658 PA2014008 Lithuania ⤷  Try a Trial PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013 11 15 EU/1/13/884/005 - EU/1/13/884/008 20131115
1651658 637 Finland ⤷  Try a Trial
1651658 164 1-2014 Slovakia ⤷  Try a Trial PRODUCT NAME: KANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/008 20131115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.